Related Experiment Video

Updated: Jul 19, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling

Peter C Gray1, Gidi Shani, Kevin Aung

  • 1Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA. gray@salk.edu

Molecular and Cellular Biology
|October 13, 2006
PubMed

Insights

Cripto, a cancer-promoting oncoprotein, blocks the tumor-suppressing activity of transforming growth factor beta (TGF-beta) by preventing its receptor binding. This discovery reveals a new mechanism by which Cripto drives tumor growth.

Area of Science:

  • Molecular Biology
  • Oncology
  • Developmental Biology

Background:

  • Cripto is an oncoprotein involved in embryogenesis and tumorigenesis.
  • It functions as a coreceptor for transforming growth factor beta (TGF-beta) ligands during development.
  • Cripto is known to promote tumor growth through various signaling pathways.

Purpose of the Study:

  • To investigate a novel mechanism by which Cripto influences tumor suppressor functions.
  • To determine if Cripto directly interferes with TGF-beta signaling pathways.

Main Methods:

  • Binding assays to assess Cripto and TGF-beta interaction.
  • Analysis of TGF-beta receptor (TbetaRI) association.
  • Cell-based assays to measure TGF-beta signaling and cytostatic effects.
  • Small inhibitory RNA (siRNA) to disrupt Cripto expression.

Main Results:

  • Cripto directly binds to TGF-beta, inhibiting its association with the TbetaRI receptor.
  • Cripto suppresses TGF-beta signaling and its cytostatic effects in mammary epithelial cells.
  • Disruption of Cripto expression using siRNA enhances TGF-beta signaling.

Conclusions:

  • Cripto inhibits the tumor suppressor function of TGF-beta by blocking its receptor binding.
  • Endogenous Cripto plays a role in restraining TGF-beta responses, suggesting a novel oncogenic mechanism.
  • Targeting Cripto may offer a new strategy for cancer therapy by restoring TGF-beta tumor suppressor activity.

More Related Videos

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...